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Abstract
Severe calcific aortic stenosis (AS) is commonly seen in the elderly population, 
and as human longevity increases, the prevalence of severe AS is bound to increase. 
Symptomatic severe AS, if left untreated, carries high mortality with 2-year sur-
vival below 50%. Surgical aortic valve replacement (SAVR) had been the standard 
of care for such patients with excellent outcome. As the patient’s comorbidities 
increase, so does surgical risk for SAVR. Since its first human use in 2002 and com-
mercial approval in 2007 (CE mark, Europe), transcatheter aortic valve replace-
ment (TAVR) has come up as an excellent alternative to SAVR in patients with 
higher surgical risk profile. Iterations in device design added to enhanced operator 
experience can be attributed towards improved clinical outcomes. Indications for 
TAVR continues to expand and now includes patients with intermediate surgical 
risk as well. This chapter discusses indications and evidence for TAVR and touches 
upon patient selection and complications after TAVR.
Keywords: severe aortic stenosis, transcatheter aortic valve replacement,  
indications of TAVR, complications of TAVR, trials on TAVR
1. Introduction
A population-based study done by Eveborn et al. demonstrated an increase in 
the prevalence of AS with age, from 0.2% at 50–59 years to 9.8% at 80–89 years [1].
Prevalence of any AS and severe AS from pooled data involving multiple 
studies was shown to be 12.5 and 3.4% respectively among people of age >75. 
Approximately half to one-third of patients with severe AS may be asymptomatic at 
the time of diagnosis [2].
Due to long asymptomatic period associated with severe Aortic stenosis, patients 
may not report any overt symptoms, or compensate for their decreased exertional 
capacity by slowing down their daily activities attributing it to normal aging. 
Addressing symptom onset in patients with severe AS is extremely important as the 
onset of symptoms markedly decreases survival unless aortic valve replacement is 
performed.
Early observation done by Ross and Braunwald [3] showed that patients with 
angina have a 50% 5-year survival rate without AVR, those with syncope have 50% 
3-year survival. Heart failure carries worse prognosis with mean survival rate of less 
than 2 years without AVR.
Aortic Stenosis - Current Perspectives
2
While SAVR is considered standard of care for management of symptomatic 
severe aortic stenosis, one-third of patients with severe AS with indications for 
SAVR may be denied surgery in view of advanced age and comorbidities.
Catheter-based balloon aortic valvuloplasty (BAV) was developed in 1985 as 
a less invasive solution for patients with symptomatic severe AS who were denied 
SAVR.
High rates of recurrence (80%) at 1 year associated with BAV hindered its wide-
spread adaptability and search for other less invasive therapeutic option for severe 
AS patients was continued.
Contemporary indications for BAV are listed in Table 1. Currently, BAV is 
reserved for use as a bridge-to-decision to provide more definitive therapy for AS 
and for patients with contraindications for TAVR in whom relief of Aortic obstruc-
tion will improve quality of life.
2. TAVR: early concepts
To circumvent restenosis after BAV, a combination of stent frame and valve 
within was thought as an alternative. This arrangement could potentially implant an 
aortic valve in place of diseased native aortic valve using minimally invasive cath-
eterization technique, thus avoiding high morbidity and mortality associated with 
high risk SAVR. Routine observation of high-pressure balloon inflation (4–5 atmo-
spheres) leading to opening of all calcified aortic valves in a circular fashion led to 
the concept of TAVR [4].
In 1992, Andersen and colleagues [5], used a hand-made porcine valve contained 
within a metallic mesh and successfully implanted at various cardiac sites in a pig 
model. This was the first evidence of use of a stented valve.
In 1999 percutaneous valve technologies (PVT) designed early models of bal-
loon expandable transcatheter heart valve (THV) [4].
The first human implantation of a percutaneous stented valve to a degenerated 
right ventricle-to-pulmonary artery conduit was done in 2000 by Bonhoeffer and 
colleagues [6]. This was a bovine jugular valve mounted on stent platform.
After initial success with the sheep model, Dr. Alain Cribier and his team 
performed the first successful TAVR in human using a balloon expandable THV on 
16th April 2002 as a bailout procedure after failed emergency BAV [4].
Table 1. 
Indications for balloon aortic valvuloplasty (BAV).
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3. Evolution of  TAVR: indications and clinical trial evidence for TAVR
After initial success with the Sheep model, first human implantation with the 
balloon expandable Edwards valve was done on 16th April 2002 after failed emer-
gency BAV as a bailout procedure [4].
After encouraging initial results, Dr. Cribier and team were able to recapitulate 
TAVR in a few patients. Worldwide demonstrations of this innovative therapy led 
to its increased acceptance. TAVR was transforming from a crazy idea to a viable 
therapy option. The Cribier valve technology was acquired by Edwards Lifesciences 
(Irvine, CA) for further development, and the THV was further marketed as 
Edwards Sapien valve.
Simultaneously scientists from Europe were working on a self-expandable 
valve (CoreValve, Medtronic, Inc.; Minneapolis, MN) platform as an alternative to 
balloon expandable valve since 2004 and human implantations were being done 
successfully.
As the number of TAVR implantations increased, data from multiple small 
studies and registries like SOURCE, ADVANCE, FRANCE I and FRANCE II showed 
procedural success (30 days survival) ranging from 67–92%.
With the available data, the European CE mark authorization was granted in 
August 2007 for the Edwards Sapien balloon expandable THV with the transfemo-
ral RetroFlex delivery system and in January 2008 for use with the transapical 
Ascendra delivery device.
PARTNER was the first randomized trial that compared TAVR with standard 
therapy. Cohort B of this landmark trial demonstrated superiority of TAVR over 
medical therapy in patients with severe symptomatic AS who were considered 
extreme (or prohibitive) risk for SAVR. At 1 year follow up, absolute risk reduc-
tion in all-cause mortality of 20% was observed, a finding which held true even at 
5 years follow up [7].
Cohort A of PARTNER trial compared TAVR with SAVR and showed that TAVR 
was non-inferior to SAVR in patients with high surgical risk (society of thoracic 
surgeons (STS) score >8%). CoreValve extreme risk trial data showed benefit of 
TAVR with reduction in all-cause mortality.
In November 2011, United States Food and Drug Administration (US FDA) 
approved TAVR as a treatment option for patients with symptomatic severe AS who 
were considered inoperable for SAVR. Favourable clinical data using self-expanding 
THV CoreValve (Medtronic) led to its USFDA approval in 2014 on similar patient 
subset.
With the available evidence from randomised control trials (RCTs) and multiple 
registry data, TAVR was given Class I LOE B recommendation in patients with 
prohibitive (not suitable for SAVR) and increased surgical risk by ESC guidelines 
[8] and Class I LOE A by ACC/AHA guidelines [9].
Another important observation noted in PARTNER 1 trial was diminishing 
survival benefit of TAVR with higher STS score. This led to stress more importance 
on patient selection.
Intermediate surgical risk (STS score ≥4–8%) patients with symptomatic severe 
AS were enrolled in PARTNER 2 trial comparing TAVR using second generation 
Sapien valve (Sapien XT) with SAVR along with subgroup analysis of transfemoral 
and transthoracic cohorts. All-cause mortality in TAVR arm was non-inferior to 
SAVR at 2 years with comparable stroke and permanent pacemaker rates.
The SURTAVI (surgical replacement and transcatheter aortic valve implanta-
tion) trial used Self-expandable CoreValve and enrolled patients with symptomatic 
severe AS with intermediate surgical risk and showed all-cause mortality in TAVR 
group non-inferior to SAVR at 1 and 2 years.
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PARTNER 2 and SURTAVI trials also showed a favourable decreasing trend in 
all-cause mortality and post-procedure stroke rates (refer to Table 2).
ACC/AHA has given Class II LOE (level of evidence) A recommendation for 
TAVR in intermediate-risk population [9].
With the availability of 5-year data on TAVR showing good valve durability, 
focus of attention shifted to extend the benefit of TAVR to low-risk population with 
severe AS.
NOTION trial [10] and low-risk TAVR trial [11] evaluated the role of TAVR in 
low-risk population (STS score <4%).
NOTION trial is one of the earliest randomized trials, started recruiting patients 
in 2009 in a single centre. NOTION trial enrolled patients with symptomatic severe 
AS with low surgical risk and randomized them to TAVR versus SAVR. All-cause 
mortality at 1 year seen in this study was lower in TAVR arm compared to SAVR, an 
effect that persisted at 5 years.
The post-procedure permanent pacemaker implantation (PPI) rates and PVL 
(paravalvular leak) were higher in the TAVR group. Despite higher PPI and PVL 
rates, the all-cause mortality was lower with TAVR than SAVR. Higher PPI rates 
were because of an overenthusiastic approach for pacemaker implantation in view 
of lack of experience during those days.
The above-mentioned trials showed a consistent reduction in 30 days all-cause 
mortality attributed to improved technical advances, procedural skills and better 
patient selection (refer to Table 2).
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A valve in valve (ViV), by virtue of the procedure being a re-do sternotomy, 
with patients typically in their 70 and 80s age, they usually fall into an intermedi-
ate risk category for surgical treatment. Most of the patients with degenerated bio 
prosthetic aortic valve qualify for TAVR.
The main issues with ViV are under expansion of the valve leading to higher 
gradients and a higher risk of coronary obstruction.
Bicuspid aortic valve (BiV), not approved, TAVR had been used off-label in BiV.
Issues related to the use of TAVR in BiV are:
Large annulus with severe and asymmetric calcification or presence of raphe can 
hinder with positioning and expansion of the valve that can lead to PVL or annulus 
rupture.
Increased risk of aortic dissection or rupture in view of concomitant aortopathy.
In view of relatively young patients with longer life expectancy, the durability of 
TAVR valve is still a concern.
A study by Ravi et al., which included 435 patients with BiV, showed higher 
30 days all-cause mortality with off label TAVR (8.5%) when compared with on 
label TAVR (6.1%) [12].
Outcomes are not as favourable as tricuspid valve, still a valid alternative in 
patients with higher surgical risk profile.
Table 2. 
Clinical trials data.
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4. Patient selection for TAVR
Patient evaluation is directed towards identifying patients where significant 
improvement in the quality and duration of life is expected with AVR and avoid 
unnecessary intervention where the benefit is unlikely due to other confounding 
co-morbidities.
Extreme comorbidities that overwhelm the benefit of TAVR may render the 
procedure futile as shown in PARTNER cohort B.
The essential components for patient selection include:
1. Clinical risk stratification with emphasis on heart team
2. Geriatric risk stratification
3. Anticipated clinical benefit and
4. Assessment of patient’s goals and preferences
5. Anatomic assessment: MDCT as standard. 3D TEE as an alternative.
a. Accurate valve sizing
b. Vascular access planning
4.1 Clinical risk stratification
Important components of clinical risk stratification are mentioned in Table 3.
STS-PROM and Euroscore II are the two most commonly used integrated risk 
scoring calculators used to assess surgical risk.
STS risk scoring system had been extensively utilized in clinical decision making 
for TAVR. SAVR, components of which are showed in Table 4.
STS score <4% is low risk.
≥4%, <8% is intermediate risk.
>8% is high risk.
Table 3. 
Clinical predictors of increased risk.
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Concept of heart team: doctors from various specialties as a team need to evalu-
ate TAVR patients.
Multidisciplinary team approach provides an opportunity for active participa-
tion of doctors from multiple specialties and share views on different aspects of 
patient health care and also to counsel patient relatives on an anticipated line of 
management.
The team should consist of referring physician, Clinical Cardiologist, 
Interventional cardiologist, cardiothoracic surgeon, Cardiac anaesthesiologist, 
dedicated cardiac imaging specialist, Valve clinic coordinator, dedicated nursing 
and catheterisation laboratory team.
4.2 Geriatric risk stratification
Beyond the traditional co-morbidities like DM and HTN, the elderly population 
also need particular attention in terms of advanced frailty, disability in activities 
of daily living, malnutrition, mobility impairment, low muscle mass and strength, 
cognitive impairment and mood disorders.
The commonly used assessment tools are shown in Table 5.
4.3 The anticipated benefit of TAVR
Trial evidence consistently shows, treatment with TAVR in patients with symp-
tomatic severe AS results in reduction of all-cause mortality, improved duration of 
survival.
Patients symptomatic because of severe AS not because of other comorbidities 
have the greatest symptomatic benefit.
Patient pre-operative symptom status can be assessed by Kansas city cardiomy-
opathy questionnaire (KCCQ ) [13] and can be followed up linearly.
Table 4. 
Variables included in STS PROM and variables not included in STS PROM.
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4.4 Patients goals and preferences
The assessment of futility must include consideration of patient’s values, goals, 
and preferences.
Shared decision-making requires both patient and provider share information, 
work toward a consensus and reach agreement on the course of action.
In the TAVR population, when benefit in symptom relief aligns with a patient’s 
goals, care may not futile.
However, when life prolongation and symptom relief is not anticipated, care 
may be futile.
TAVR is not recommended in patients with a life expectancy of <1 year, or if the 
benefit of TAVR will be less obvious in the backdrop of multiple co-morbidities.
4.5 Anatomic assessment
Assessment of valve calcification, valve anatomy, annulus size, coronary height, 
an angle of implantation, size of sinuses of Valsalva, ascending aorta and peripheral 
vascular access by multidetector computerized tomography scan (MDCT) is an 
integral part of pre TVAR work up.
4.5.1 Aortic annulus
Annulus is a virtual ring formed by basal hinge points of the valve cusps. The 
measurement of annulus size is a very important step as it determines the size of the 
TAVR valve.
Prosthesis undersizing causes the risk of significant Paravalvular leak (PVL) or 
valve embolization, if oversized, disruption of the aortic root and cause annular 
rupture or impingement on conduction system and may cause bundle branch block 
or complete heart block.
Table 5. 
Geriatric assessment tools.
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3D TEE and MDCT are the two most commonly used imaging methods for 
annulus measurement.
MDCT is a non-invasive procedure, the ability to measure annulus during any 
part of the cardiac cycle and provide additional information like valve calcification, 
distribution of valve calcification, sizes of sinus of valsalva (SOV), coronary ostia 
distance from the annulus, makes it imaging of choice unless contraindicated in 
view of kidney injury [14].
4.5.2 Vascular access planning
MDCT because of excellent resolution provides a virtual roadmap for vascula-
ture and allows identification of vessel size, tortuosity, calcification, and luminal 
diameter, which allows the planning of access routes with a view to minimizing 
vascular complication rate.
5. Complications of TAVR
TAVR has seen an overall decline in peri-procedural complications over time, 
partly owing to newer technology and expertise.
Complications associated with TAVR are as listed in Table 6.
According to transcatheter valve therapy (TVT data), 30-day in-hospital mor-
tality has decreased from 7.5% in 2012 to 4.6% in 2015 [15].
This part of the chapter briefly reviews about important complications post TAVR.
5.1 Major vascular access site complications
Access site complications incidence depends upon the method of localization and 
the location of the puncture site, the need for multiple punctures and the size of the 
sheath used. The incidence of major vascular complications showed a decreasing trend 
attributed to technical innovations reducing sheath size and valve delivery systems.
Table 6. 
Complications of TAVR.
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The overall major vascular complication rate was 17% in PARTNER 1 trial, 
decreased to 2.5% in low-risk TAVR trial [11], 2018 due to improvements in the 
sheath and valve delivery systems.
5.2 Permanent pacemaker implantation (PPI)
Need for PPI arises due to a complex interaction of the valve with the conduction 
system.
The incidence of PPI has not decreased as expected, compared with other 
complications. Changes in the valve design to prevent PVL and position of valve 
implantation contributed for PPI.
PPI incidence appears to increase with the oversizing of the valve and changes in 
valve design to prevent PVL. Shallow implantation and improvement in technical 
skill could decrease the incidence of PVL as shown in the REPRISE trial.
PPI frequency varies in relation to the valve type used. Balloon Expandable valve 
has a relatively less incidence of PPI at the cost of higher valvular gradients.
The incidence of new PPI post-TAVR was 6–10% in PARTNER 1 and PARTNER 
2 trials which is similar to 5% seen in low-risk TAVR study [11].
The requirement of PPI has been associated with increased hospital stay and 
financial burden but has not been shown to increase mortality conclusively.
5.3 Paravalvular leak (PVL)
PVL occurs because of the difference in the shape of the valve which is circular 
compared to the elliptical aortic annulus.
The incidence of PVL is consistently shown to be higher with TAVR than SAVR 
in all landmark trials of TAVR.
Valve size, aortic valve distribution of calcium and implantation depth were 
predictive of post TAVR PVL [16].
Precise annulus sizing by appropriate aortic imaging pre-TAVR is fundamental 
to prevent PVL. With the use of newer imaging technology and understanding of 
the factors involved the incidence of moderate or severe PVL decreased 12.5% in 
PARTNER B to <1% in low-risk TAVR data [11]. Out of 12.5% moderate to severe 
PVL in PARTNER cohort B only 0.7% have severe leak, severe PVL causing an 
increase in mortality or need for re-intervention is very rare.
5.4 Stroke
Stroke is one of the most devastating complication post-TAVR, it causes an 
increase in mortality, significant worsening of quality of life and disability.
A stroke occurs due to the embolization of plaque contents from atheroma 
disrupted during delivery system manipulations. Early trial PARTNER 1 used a 
balloon-expandable valve with a 22-24F delivery catheter and showed a 30-day 
stroke risk of 5.5–6.2% [7].
The risk of stroke decreased over the years with increasing operator experience, 
advancements in valve technology, and improvement in patient selection.
PARTNER 2 and CoreValve studies used Sapien XT and CoreValve which used 
18F delivery catheter and showed a 30-day risk of stroke around 4% [17–19].
A study on the timing of stroke post-TAVR by Samir et al. showed that of strokes 
occurring within 30 days post-TAVR, 64% were diagnosed within 2 days and 85% 
were diagnosed within 1 week, the risk of stroke after the initial peri-procedural 
period is not high [20]. More balloon post dilations and lack of dual antiplatelet 
therapy before the procedure were associated with a higher risk of early stroke [20].
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Newer advances like Sentinel cerebral protection system are recently approved 
by the US FDA and are commercially available.
The Sentinel study investigated the role of Sentinel CPS (cerebral protection 
system) but failed to show a reduction in the median total new lesion volume on 
MRI. So In view of the lack of robust evidence regarding the efficacy of CPS, the 
choice of using neuroprotection in TAVR requires an individualized risk-benefit 
analysis.
Investigations therapies like protecting aortic arch vessels with CPS, excluding 
the LAA and refining post procedural antithrombotic strategy may aid in a further 
reduction in stroke incidence.
5.5 Durability
Structural valve deterioration is defined as any change in valve function result-
ing from an intrinsic abnormality leading to an intervention.
Increase in a mean gradient to >20 mm Hg or increase >10 mm Hg from baseline, 
an appearance of new valvular regurgitation constitutes SVD.
Rising interest for the use of TAVR in low-risk population makes durability of 
valve an important concern where the life expectancy of the patients would be more 
than 15 years. Five-year data from PARTNER 1 trial showed stable valve area and 
mean transvalvular gradient throughout the follow-up. The mean valve area was 
1.52 cm2 and the mean gradient was 10 mm Hg at 5 years and no events of clinical 
thrombosis of the TAVR valve [7].
Any increase in valvular gradients should warrant imaging workup for valve 
thrombosis. Data from multicentre registry showed, an incidence of VHD of 4.5% 
(overall VHD) and 2.8% within the first year (early VHD) [21].
Makkar et al. reported hypo-attenuated leaflet thickening (HALT) and reduced 
leaflet motion (RELM) in transcatheter valves, evaluated by four-dimensional 
volume-rendered computer tomography [22]. The effect of this finding on clinical 
outcomes needs further investigation.
Walksman et al. reported a 14% incidence of HALT and 11.2% RELM at 30 days 
post-TAVR, but were asymptomatic clinically.
Multivariate analysis showed the absence of anticoagulation at discharge, valve 
size <23 mm, a valve in valve procedure and greater BMI as predictors of transcath-
eter valve hemodynamic deterioration post-TAVR [21].
5.6 Miscellaneous
5.6.1 Annular rupture
Non-existent with self-expandable valves except in cases where pre or post-
dilation is performed.
Because of the use of newer imaging modalities accurate sizing of the balloon, 
an annular rupture is a very rare phenomenon.
5.6.2 Valve embolization
Device embolization was defined as, Movement of valve prosthesis during or 
after deployment such that it loses contact with the aortic annulus. A study by 
Makkar et al., out of 2,554 patients who underwent TAVR, valve embolization was 
noted in 1% of patients. Technical factors like undersized valve and complex aortic 
valve anatomy, incomplete balloon inflation, and pacing failure were associated 
with valve embolization [23].
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5.6.3 Coronary obstruction
Symptomatic coronary obstruction following TAVR is rare but a life-
threatening complication. Multicentre registry data shows an incidence of 0.6%. 
It was observed more frequently with balloon expandable valve and in those 
with a previous surgical prosthesis [24]. Low lying coronary ostium and shallow 
sinus of Valsalva were anatomical factors associated with the risk for coronary 
obstruction [24].
5.6.4 Trans oesophageal echo (TEE) related complications
The incidence of complications with TEE is <1%. Dental trauma, oral bleeding, 
oesophageal erosions and rarely oesophageal rupture.
5.6.5 Anaesthesia-related complications
Respiratory dependence, hypotension, nausea and vomiting are among com-
mon, complete description of anaesthesia related complications is beyond the scope 
of this chapter.
6. Conclusion
TAVR, a novel approach started as an impossible idea, witnessed a remark-
able journey and now is an established therapy in management of symptomatic 
severe Aortic stenosis patients. Outcomes post TAVR are bound to get better as 
technology improves and expertise increases. “TAVR first approach may be the 
future.”
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Appendix
AS aortic stenosis
STS PROM society of thoracic surgeons, predicted risk of mortality
MI myocardial infarction
V tach/V fib ventricular tachycardia/ventricular fibrillation
CT surgeon cardiothoracic surgeon
PPI permanent pacemaker implantation
PVL paravalvular leak
VARC valve academic research consortium
CPS cerebral protection system
LAA left atrial appendage
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VHD valve hemodynamic deterioration
SVD structural valve degeneration
TAVR transcatheter aortic valve replacement
HALT hypo attenuated leaflet thickening
RELM reduced leaflet motion
COPD chronic obstructive pulmonary disease
CABG coronary artery bypass graft
BAV balloon aortic valvuloplasty
THV transcutaneous heart valve
PVT percutaneous valve technologies
PARTNER placement of aortic transcatheter valve trial
SOURCE Sapien aortic bioprosthesis European Outcome Registry
NOTION Nordic aortic valve intervention trial
SURTAVI surgical replacement and transcatheter aortic valve implantation
SOV sinus of valsalva
TVT transcatheter valve therapy
TEE trans oesophageal echo
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